Denali Advisors LLC Has $27,000 Stake in Organon & Co. (NYSE:OGN)

Denali Advisors LLC trimmed its stake in shares of Organon & Co. (NYSE:OGN) by 80.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,430 shares of the company’s stock after selling 5,817 shares during the period. Denali Advisors LLC’s holdings in Organon & Co. were worth $27,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lindbrook Capital LLC raised its stake in shares of Organon & Co. by 348.3% during the fourth quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after buying an additional 1,428 shares during the last quarter. Gladius Capital Management LP boosted its position in shares of Organon & Co. by 65.1% in the 4th quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock worth $31,000 after purchasing an additional 858 shares during the last quarter. Tompkins Financial Corp grew its stake in shares of Organon & Co. by 450.7% during the first quarter. Tompkins Financial Corp now owns 2,412 shares of the company’s stock worth $45,000 after purchasing an additional 1,974 shares during the period. GAMMA Investing LLC acquired a new stake in shares of Organon & Co. during the fourth quarter worth $38,000. Finally, Hexagon Capital Partners LLC increased its holdings in Organon & Co. by 123.9% in the first quarter. Hexagon Capital Partners LLC now owns 2,628 shares of the company’s stock valued at $49,000 after purchasing an additional 1,454 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. The Goldman Sachs Group boosted their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Piper Sandler raised their price objective on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th.

Organon & Co. Trading Up 0.9 %

Organon & Co. stock traded up $0.19 during mid-day trading on Wednesday, hitting $20.31. 890,360 shares of the company’s stock were exchanged, compared to its average volume of 2,368,489. The firm has a market capitalization of $5.22 billion, a P/E ratio of 5.02, a PEG ratio of 0.90 and a beta of 0.85. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The company has a quick ratio of 1.15, a current ratio of 1.65 and a debt-to-equity ratio of 181.35. The company’s 50 day simple moving average is $20.55 and its 200-day simple moving average is $18.22.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.31. The firm had revenue of $1.62 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. On average, equities analysts anticipate that Organon & Co. will post 4.3 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 13th. Stockholders of record on Monday, May 13th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 5.51%. The ex-dividend date was Friday, May 10th. Organon & Co.’s payout ratio is 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.